Navigation Links
Chemo Patients Pose Potential Public Health Risk

NEWPORT, R.I., Sept. 19, 2013 /PRNewswire-iReach/ -- In its second edition of "Safe Management of Wastes from Health-Care Activities," released in August, the World Health Organization (WHO) singled out contact with residual amounts of chemotherapy drugs as a significant risk requiring collection, containment and proper disposal in order to avoid exposure "through contact with body fluids and secretions [urine, feces and vomit] of patients undergoing chemotherapy."

Genotoxic/cytotoxic compounds, most commonly found in chemotherapy drugs, work by either mutating or killing cells. Unlike poisons, which can be safe when exposure is limited to tiny amounts, genotoxins/cytotoxins act more like "chemical germs," where even minimal exposure can cause a devastating chain reaction. The risk from contact to an otherwise healthy person is especially heightened when there is a significant amount of cell development happening — for example, among children and women of childbearing age.

According to the WHO report, any wastes produced by these patients within 48 hours of drug administration, and in some cases for up to a week, should be considered genotoxic.

Despite the otherwise well-regulated and well-managed handling of dangerous medical waste, chemotherapy patients treated with any of more than two dozen different chemotherapy drugs who return home after outpatient treatment can inadvertently but easily expose others to genotoxic contamination through seemingly benign occurrences such as urine splashed on a bathroom floor, clean up after an episode of vomiting, or the handling of bed sheets or a bedpan for a patient unable to use a bathroom.

The WHO report address what many in the field of chemotherapy-based treatment have long acknowledged as a dangerous "blind spot."
The human body can only destroy a portion of these genotoxic drugs. The rest passes out of the patient in urine, feces, vomit, or even sweat. The waste will still have enough dangerous drug to kill developing cells and/or cause mutations in vulnerable members of our population, especially fetuses and babies.

The WHO has done a great public service by stepping up and publicly declaring what many of us in the field have long known — this is a serious risk.

WHO core principles "require that everyone associated with financing and supporting health-care activities should provide for the costs of managing health-care waste. This is the duty of care. Manufactures also share a responsibility to take waste management into account in the development and sale of their products and services."

The WHO goes on to identify those who have a special responsibility to ensure safe collection, containment and disposal of these wastes, placing much of that responsibility with the chief pharmacist. "The chief pharmacist also has the special responsibility of ensuring that genotoxic products are used safely, and that genotoxic waste is managed safely," according to the WHO.

Jim Mullowney is the founder and CEO of Newport-based Pharma-Cycle Inc

Media Contact: Jim Mullowney, Pharma-Cycle, Inc., 617-755-0883,

News distributed by PR Newswire iReach:

SOURCE Pharma-Cycle, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Big Pharma to Come Together at ChemOutsourcing 2013 in Long Branch, New Jersey, Sept 16-19
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. ChemOutsourcing Announces 100 CMO and CRO Exhibitors for September 2013 Show in Long Branch, New Jersey
4. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
7. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
8. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
9. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
10. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015   Royal Philips (NYSE: ... the industry,s first MRI guided user interface and automatic ... patients with MR Conditional implants, such as knee and ... 2015 Radiological Society of North America Annual Meeting (RSNA) ... supports diagnostic confidence of this growing patient population. ScanWise ...
(Date:11/30/2015)... 2015 Nautilus Medical Inc. today announced worldwide ... ( ). The release of MatrixRay to the ... (Radiology Society North America) in Chicago ... --> --> MatrixRay ... to radiology studies worldwide via a peer-to-peer exchange network ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The ... prostate cancer education and prevention—is joining forces with the award-winning creator and writer ... elegance on December 7, 2015 at the Union League of Philadelphia. , ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical Pathology (ASCP) ... AIDS Day 2015. On Nov. 30, ASCP shared its “Give a minute. Get tested. ... Day and the importance of getting tested for HIV. , ASCP has asked members ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... as their exclusive channel partner for the Nutraceutical Specialties products into oral solid ... US, effective immediately. , “We are pleased to announce our expanded distribution ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting a “A ... a child’s exposure limits. , The original Nov 2015 CR story titled, “Does ...
(Date:11/30/2015)... Calif. (PRWEB) , ... November 30, 2015 , ... ... and Analytics for the last 15 years, announced today that Michigan-based Family Health ... provider of care for over 45 years, FHC was awarded the largest Affordable ...
Breaking Medicine News(10 mins):